Search clinical trials for: Naltrexone

Total 482 results

Yale University
National Institute on Drug Abuse (NIDA); Baystate Medical Center

Completed

Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations (NewHope)

HIV | Opioid Dependence | AIDS | Drug Dependence

United States
Riyadh Colleges of Dentistry and Pharmacy

Completed

Effectiveness of Nanohydroxyapetite Paste on Reducing Dentin Hypersensitivity

Dentin Hypersensitivity

Saudi Arabia
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone

Opioid Dependence

United States
Yale University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Naltrexone and Memantine Effects on Alcohol Drinking Behaviors

Alcohol Drinking

United States
University of Minnesota
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); American...

Completed

Naltrexone and Hypoglycemia in Type 1 Diabetes (Naltrexone)

Type 1 Diabetes | Hypoglycemia Unawareness

United States
Jinnah Postgraduate Medical Centre

Completed

Efficacy of Low Dose Naltrexone in Psoriasis

Psoriasis

Pakistan
University of California, Los Angeles
Alkermes, Inc.

Completed

Injectable Pharmacotherapy for Opioid Use Disorders (IPOD) (IPOD)

Opioid Use Disorders

United States
Brigham and Women's Hospital
VA Boston Healthcare System

Withdrawn

Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory Arthritis

Arthritis, Rheumatoid | Osteoarthritis | Arthritis, Psoriatic

United States
Bausch Health Americas, Inc.

Completed

Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac Repolarization

Healthy Volunteers

United States
Bausch Health Americas, Inc.

Completed

Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan

Healthy Adults

United States
Bausch Health Americas, Inc.

Completed

Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose

Healthy Subjects

United States
Bausch Health Americas, Inc.
Pfizer

Completed

A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients

Advanced Illness Patients With Opioid Induced Constipation

United States
University of Pennsylvania

Completed

Understanding Treatment Response With Naltrexone Among White Alcoholics (DEFINE II)

Alcoholism

United States
Herlev Hospital

Completed

Calcium Electroporation for Treatment of Cutaneous Metastases

Cutaneous Metastases

Denmark
University of Pennsylvania

Completed

Managing Alcoholism in People Who Do Not Respond to Naltrexone (EXTEND)

Alcoholism

United States
RWTH Aachen University

Terminated

Study of the Opioid Modulation of the Effect of Alcohol on the Dopaminergic Reward System

Alcohol Addiction

Germany
University of Pennsylvania

Completed

Endophenotype for Alcohol Misuse in Healthy Minority Populations (DEFINE)

Healthy

United States
Alkermes, Inc.

Completed

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study

Major Depressive Disorder

United States, Australia, Canada
Yale University

Terminated

Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia (NBC)

Obesity | Diabetes Mellitus, Type 2 | Schizophrenia

United States
Lifespan
University of Rhode Island

Completed

Medication Maintenance Therapy in Community Pharmacy Settings (MATPharm)

Opioid-use Disorder

United States
University of Minnesota

Completed

Double-Blind Naltrexone in Kleptomania

Kleptomania

United States
Tristen Inagaki

Completed

An fMRI Study of Opioid-related Changes in Neural Activity

Social Acceptance

United States
University of California, Los Angeles
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Naltrexone for Individuals of East Asian Descent

Alcohol Use Disorder

United States
University of Minnesota

Completed

Food Reward in Native American Women

Obesity

United States
Mundipharma (China) Pharmaceutical Co. Ltd

Unknown

Buprenorphine Transdermal Patches Pharmacokinetic Study

Chronic Pain

China
The Taub Group

Completed

The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major Depression

Depression

United States
Timothy Smith

Completed

The Evaluation of Safety and Tolerance of Commercially Available Naltrexone Administered Daily - Assessment for CBRN Operations (TEST CANADA)

Opioid Intoxication

Canada
New York State Psychiatric Institute

Completed

Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence

Cannabis Dependence

United States
University of California, San Francisco
National Institute on Drug Abuse (NIDA)

Completed

Intermittent Naltrexone Among Polysubstance Users (Project iN)

Methamphetamine | Alcohol

United States
University of Pennsylvania
National Institute on Drug Abuse (NIDA)

Completed

Depot Naltrexone Treatment of Opioid Dependent Parolees

Opioid Dependence

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence

Opioid Dependence

United States
Yale University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention (DAWN)

Reduction in Heavy Drinking in Patients With HIV

United States
Oregon Health and Science University
National Institute on Drug Abuse (NIDA)

Completed

Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study (CHOICES)

Opioid Use Disorder | Alcohol Use Disorder

Canada, United States
University of Pennsylvania
National Institute on Drug Abuse (NIDA); St. Petersburg State Pavlov Medical...

Completed

Addiction Treatment in Russia: Oral vs. Naltrexone Implant

Opioid-Related Disorders | Heroin Dependence

United States, Russian Federation
Alkermes, Inc.

Completed

Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)

Opioid Use Disorder

United States
University of Wisconsin, Madison

Completed

Oral vs. Injectable Naltrexone for Hospitalized Veterans With Alcohol Dependence

Alcohol Dependence

United States
Oregon Health and Science University
National Institute on Drug Abuse (NIDA)

Completed

Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade

HIV | Methamphetamine Abuse

United States
Alkermes, Inc.

Completed

Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL

Opioid Use Disorder

United States
Universita di Verona
IGEA

Terminated

Electrochemoterapy With Bleomycin for the Treatment of Unresectable Pancreatic Cancer

Pancreatic Cancer

Italy
University of North Carolina, Chapel Hill
North Carolina Translational and Clinical Sciences Institute

Completed

An Open Label Trial of Bupropion and Naltrexone for Binge Drinking

Binge Drinking

United States
Alkermes, Inc.

Completed

ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals

Opiate Dependence

United States
Avekshan LLC

Completed

Study for Naltrexone on the Abuse Potential of Methylphenidate

Naltrexone | Methylphenidate Abuse

United States
University of Pennsylvania
National Institute on Drug Abuse (NIDA)

Completed

Adherence to HIV Therapy in Heroin Addicts: Oral vs XR-NTX

HIV Infections | HIV | Substance Abuse

Russian Federation
Purdue Pharma LP

Completed

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers

ECG Effects

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

Medication-Assisted Treatment for Youth With Substance Use Disorders

Opioid Use Disorder | Opioid Dependence

United States
Pfizer
Syneos Health

Completed

A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers

Healthy

Canada
University of Oslo
Norwegian Institute of Public Health; Oslo University Hospital; The Research... and other collaborators

Completed

Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway (NTX-SBX)

Opioid Dependence

Norway
Milton S. Hershey Medical Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); The...

Completed

The Effects of Naltrexone on Active Crohn's Disease (LDN)

Inflammation | Crohn's Disease

United States
Pfizer

Completed

A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers

Healthy

United States
Pfizer

Completed

Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered Naltrexone

Healthy

United States

Search clinical trials for: Naltrexone

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations